<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Chinese Medicine - Latest articles</title>
		<link>http://www.cmjournal.org</link>
		<description>The latest articles from Chinese Medicine (ISSN 1749-8546) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/11"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/10"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/9"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/8"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/7"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/6"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/5"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/4"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/3"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/2"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.cmjournal.org/content/3/1/11">
            
            <title>Recent advances in the investigation of curcuminoids</title>
			<description>More than 30 Curcuma species (Zingiberaceae) are found in Asia, where the rhizomes of these plants are used as both food and medicine, such as in traditional Chinese medicine. The plants are usually aromatic and carminative, and are used to treat indigestion, hepatitis, jaundice, diabetes, atherosclerosis and bacterial infections. Among the Curcuma species, C. longa, C. aromatica and C. xanthorrhiza are popular. The main constituents of Curcuma species are curcuminoids and bisabolane-type sesquiterpenes. Curcumin is the most important constituent among natural curcuminoids found in these plants. Published research has described the biological effects and chemistry of curcumin. Curcumin derivatives have been evaluated for bioactivity and structure-activity relationships (SAR). In this article, we review the literature between 1976 and mid-2008 on the anti-inflammatory, anti-oxidant, anti-HIV, chemopreventive and anti-prostate cancer effects of curcuminoids. Recent studies on curcuminoids, particularly on curcumin, have discovered not only much on the therapeutic activities, but also on mechanisms of molecular biological action and major genomic effects.</description>
			<link>http://www.cmjournal.org/content/3/1/11</link>
			
			 	<dc:creator>Hideji Itokawa, Qian Shi, Toshiyuki Akiyama, Susan L. Morris-Natschke and Kuo-Hsiung Lee</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:11</dc:source>
			<dc:date>2008-09-17</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-11</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/10">
            
            <title>Anti-inflammatory effects of Radix Gentianae Macrophyllae (Qinjiao), Rhizoma Coptidis (Huanglian) and Citri Unshiu Pericarpium (Wenzhou migan) in animal models</title>
			<description>Background:
KHU14, an ethanolic extract of Radix Gentianae Macrophyllae (Qinjiao), Rhizoma Coptidis (Huanglian) and Citri Unshiu Pericarpium (Wenzhou migan) was tested for its anti-inflammatory effects.
Methods:
Three out of 20 herbs were found to have anti-inflammatory effects. The formulation of these herbs, i.e. KHU14 was tested for croton oil-induced ear edema, carrageenan-induced paw edema, acetic acid-induced capillary permeability, cotton pellet and delayed type hypersensitivity.
Results:
KHU14 exhibited anti-inflammatory effects in animal models of acute and chronic inflammation. The anti-inflammatory activity of KHU14 observed was comparable to that of celecoxib. KHU14 inhibited the production of NO and PGE2 in LPS/IFN-gamma-stimulated peritoneal macrophages, and reduced edema and the amount of infiltrated cells in animal models.
Conclusion:
KHU14 exhibited anti-inflammatory effects as demonstrated in typical immunological tests for anti-inflammation in vitro and in vivo.</description>
			<link>http://www.cmjournal.org/content/3/1/10</link>
			
			 	<dc:creator>Kyoung Soo Kim, Hae In Rhee, Eun Kyung Park, Kiwon Jung, Hyo Jin Jeon, Ji-Hong Kim, Hunseung Yoo, Chang-Kyun Han, Yong-Baik Cho, Chun Jeih Ryu, Hyung In Yang and Myung Chul Yoo</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:10</dc:source>
			<dc:date>2008-09-02</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-10</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-09-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/9">
            
            <title>Recent advances in the compound-oriented and pattern-oriented approaches to the quality control of herbal medicines</title>
			<description>The current approaches to the quality control of herbal medicines are either compound-oriented or pattern-oriented, the former targeting specific components with some known chemical properties and the latter targeting all detectable components. The marker approach uses specific chemical compounds with known molecular structures, while the multi-compound approach uses both chemical compounds with known structures and those with partial chemical information e.g. retention times, mass spectra and ultraviolet spectra. Apart from chromatographic techniques, new techniques such as oscillating and electrochemistry fingerprints have been developed for quality control. Chemometric resolution methods are widely used for component deconvolution and data comparison. Pattern recognition techniques are used for authentication of herbal medicines.</description>
			<link>http://www.cmjournal.org/content/3/1/9</link>
			
			 	<dc:creator>Zhongda Zeng, Foo-tim Chau, Hoi-yan Chan, Chui-yee Cheung, Tsui-yan Lau, Shuiyin Wei, Daniel Kam-wah Mok, Chi-on Chan and Yizeng Liang</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:9</dc:source>
			<dc:date>2008-08-04</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-9</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/8">
            
            <title>Effects of ginsenosides Re and Rg3 on intracellular redox state and cell proliferation in C6 glioma cells</title>
			<description>Background:
Cellular redox state is important to cell growth and death. The growth of tumor cells may be modulated by intracellular reduced glutathione/oxidized glutathione (GSH/GSSG). The present study aims to investigate the effects of ginsenosides Re and Rg3 on cellular redox state and cell proliferation in C6 glioma cells.
Methods:
Cultured C6 glioma cells were exposed to various concentrations of either Rg3 or Re for 24 hours. Cell growth and death were measured by the BrdU incorporation assay and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay respectively. Cellular redox state was determined by free radical production using flow cytometry and GSH/GSSG using spectrofluorometry.
Results:
At a sub-lethal concentration, Re suppressed cell proliferation with a significant decrease in BrdU incorporation. Re did not increase reactive oxygen species (ROS) production but increased GSH/GSSG via increased activity of gamma glutamylcystenyl synthase (&#947;-GCS). In contrast, Rg3 increased free radical production and reduced GSH/GSSG. The effects of Rg3 were probably due to increased activity of glutathione peroxidase (GPx).
Conclusion:
Re and Rg3 alter cellular redox state of C6 glioma cells in opposite directions. Changes in cellular redox state induced by Re and Rg3 are correlated with the proliferation rates of C6 glioma cells.</description>
			<link>http://www.cmjournal.org/content/3/1/8</link>
			
			 	<dc:creator>Wai Yee Ng and Mildred S Yang</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:8</dc:source>
			<dc:date>2008-07-11</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-8</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/7">
            
            <title>Chemical markers for the quality control of herbal medicines: an overview</title>
			<description>Selection of chemical markers is crucial for the quality control of herbal medicines, including authentication of genuine species, harvesting the best quality raw materials, evaluation of post-harvesting handling, assessment of intermediates and finished products, and detection of harmful or toxic ingredients. Ideal chemical markers should be the therapeutic components of herbal medicines. However, for most herbal medicines, the therapeutic components have not been fully elucidated or easily monitored. Bioactive, characteristic, main, synergistic, correlative, toxic and general components may be selected. This article reviews the effective use of chemical markers in the quality control of herbal medicines including the selection criteria considering the roles and physicochemical factors which may affect the effective use of chemical markers.</description>
			<link>http://www.cmjournal.org/content/3/1/7</link>
			
			 	<dc:creator>Songlin Li, Quanbin Han, Chunfeng Qiao, Jingzheng Song, Chuen Lung Cheng and Hongxi Xu</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:7</dc:source>
			<dc:date>2008-06-28</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-7</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/6">
            
            <title>An optimized high-performance liquid chromatography (HPLC) method for benzoylmesaconine determination in Radix Aconiti Lateralis Preparata (Fuzi, aconite roots) and its products</title>
			<description>Background:
Benzoylmesaconine (BMA) is the main Aconitum alkaloid in Radix Aconiti Lateralis Preparata (Fuzi, aconite roots) with potent pharmacological activities, such as analgesia and anti-inflammation. The present study developed a simple and reliable method using BMA as a marker compound for the quality control of processed aconite roots and their products.
Methods:
After extraction, a high-performance liquid chromatography (HPLC) determination of BMA was conducted on a RP-C18 column by gradient elution with acetonitrile and aqueous phase, containing 0.1% phosphoric acid adjusted with triethylamine to pH 3.0.
Results:
A distinct peak profile was obtained and separation of BMA was achieved. Method validation showed that the relative standard deviations (RSDs) of the precision of BMA in all intra-day and inter-day assays were less than 1.36%, and that the average recovery rate was 96.95%. Quantitative analysis of BMA showed that the content of BMA varied significantly in processed aconite roots and their products.
Conclusion:
This HPLC method using BMA as a marker compound is applicable to the quality control of processed aconite roots and their products.</description>
			<link>http://www.cmjournal.org/content/3/1/6</link>
			
			 	<dc:creator>Ying Xie, Hua Zhou, Yuen Fan Wong, Zhongqiu Liu, Hongxi Xu, Zhihong Jiang and Liang Liu</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:6</dc:source>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-6</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/5">
            
            <title>Simultaneous determination of eight major bioactive compounds in Dachengqi Tang (DT) by high-performance liquid chromatography</title>
			<description>Background:
Dachengqi Tang (DT) is a common traditional Chinese medicine formula for expelling neire ('internal heat') in the stomach and intestines. There was no reliable analytical method available for the quality control of DT.
Methods:
A high-performance liquid chromatography (HPLC) method with a reverse phase C18 column (150 &#215; 4.6 mm) was developed. The mobile phase was methanol with 0.2% acetic acid. Eight markers including naringin, hesperidin, aloe emodin, rhein, honokiol, magnolol, emodin and chrysophanol were determined.
Results:
Regression analysis revealed a linear relationship between the concentrations of the markers and the peak area ratio of the standards and internal standard. The limit of detection (S/N = 3) and the limit of qualification (RSD &lt; 20%) ranged from 0.21 to 0.43 ng/&#956;l and 0.76 to 1.74 ng/&#956;l respectively. The recovery was between 95.6% and 103.4%. The tests on the samples from three batches of DT showed that the profiles of the markers did not vary significantly among batches.
Conclusion:
A reliable HPLC method for simultaneous determination of the eight markers in DT was developed.</description>
			<link>http://www.cmjournal.org/content/3/1/5</link>
			
			 	<dc:creator>Wenfu Tang, Meihua Wan, Zhengyan Zhu, Guanyuan Chen and Xi Huang</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:5</dc:source>
			<dc:date>2008-04-29</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-5</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/4">
            
            <title>Chinese red yeast rice (Monascus purpureus-fermented rice) promotes bone formation</title>
			<description>Background:
Statin can induce the gene expression of bone morphogenetic protein-2. Red yeast rice (RYR, Hongqu), i.e. rice fermented with Monascus purpureus, contains a natural form of statin. This study demonstrates the effects of RYR extract on bone formation.
Methods:
Bone defects were created in the parietal bones of two New Zealand white rabbits. In the test animal, two defects were grafted with collagen matrix mixed with RYR extract. In the control animal, two defects were grafted with collagen matrix alone. UMR 106 cell line was used to test RYR extract in vitro. In the control group, cells were cultured for three durations (24 hours, 48 hours and 72 hours) without any intervention. In the RYR group, cells were cultured for the same durations with various concentrations of RYR extract (0.001 g/ml, 0.005 g/ml and 0.01 g/ml). Bicinchoninic acid (BCA) assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and alkaline phosphatase (ALP) assay were performed to measure total protein, mitochondrial activity and bone cell formation respectively.
Results:
The test animal showed more formation of new bone in the defects than the control animal. RYR significantly increased the optical density in the MTT assay and ALP activity in vitro.
Conclusion:
RYR extract stimulated new bone formation in bone defects in vivo and increased bone cell formation in vitro.</description>
			<link>http://www.cmjournal.org/content/3/1/4</link>
			
			 	<dc:creator>Ricky WK Wong and Bakr Rabie</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:4</dc:source>
			<dc:date>2008-03-29</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-4</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/3">
            
            <title>Metabolic profiling reveals therapeutic effects of Herba Cistanches in an animal model of hydrocortisone-induced 'kidney-deficiency syndrome'</title>
			<description>Background:
Herba Cistanches (Roucongrong) is effective in treating Shenxu Zheng ('kidney-deficiency syndrome'). However, the mechanisms and systemic metabolic responses to the herbal intervention are unclear.
Methods:
Using GC-MS-based metabolic profiling, we investigated the metabolic responses to Herba Cistanches intervention in a rat model of the hydrocortisone-induced 'kidney-deficiency syndrome'.
Results:
The metabolic profiles of the rats after hydrocortisone injection deviated from the pre-dose metabolic state at different time points, ranging from day 1 to day 10, whereas the metabolic profiles of the rats treated with both hydrocortisone and water extract of Herba Cistanches returned to the pre-dose state on day 10.
Conclusion:
The intervention of Herba Cistanches caused a systemic recovery from the hydrocortisone-induced metabolic perturbation in rats. This study also demonstrates that metabolic profiling is useful in studying therapeutic mechanisms of herbal medicines.</description>
			<link>http://www.cmjournal.org/content/3/1/3</link>
			
			 	<dc:creator>Yunping Qiu, Minjun Chen, Mingming Su, Guoxiang Xie, Xin Li, Mingmei Zhou, Aihua Zhao, Jian Jiang and Wei Jia</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:3</dc:source>
			<dc:date>2008-03-10</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-3</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/2">
            
            <title>A pilot study on using acupuncture and transcutaneous electrical nerve stimulation (TENS) to treat knee osteoarthritis (OA)</title>
			<description>Background:
The present study tests whether a combined treatment of acupuncture and transcutaneous electrical nerve stimulation (TENS) is more effective than acupuncture or TENS alone for treating knee osteoarthritis (OA).
Methods:
Thirty-two patients with knee OA were randomly allocated to four groups. The acupuncture group (ACP) received only acupuncture treatment at selected acupoints for knee pain; the TENS group (TENS) received only TENS treatment at pain areas; the acupuncture and TENS group (A&amp;T) received both acupuncture and TENS treatments; the control group (CT) received topical poultice (only when necessary). Each group received specific weekly treatment five times during the study. Outcome measures were pain intensity in a visual analogue scale (VAS) and knee function in terms of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
Results:
The ACP, TENS and A&amp;T groups reported lower VAS and WOMAC scores than the control group. Significant reduction in pain intensity (P = 0.039) and significant improvement in knee function (P = 0.008) were shown in the A&amp;T group.
Conclusion:
Combined acupuncture and TENS treatment was effective in pain relief and knee function improvement for the sampled patients suffering from knee OA.</description>
			<link>http://www.cmjournal.org/content/3/1/2</link>
			
			 	<dc:creator>Kazunori Itoh, Satoko Hirota, Yasukazu Katsumi, Hideki Ochi and Hiroshi Kitakoji</dc:creator>
			
			<dc:source>Chinese Medicine 2008, 3:2</dc:source>
			<dc:date>2008-02-29</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-2</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
